Publications by authors named "B Zurawski"

Claim this Profile
N
Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trial.
Karim Fizazi, Fred Saad, Teresa Alonso-Gordoa, Bogdan Żurawski, Philippe Barthélémy

Lancet Oncol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Capivasertib plus paclitaxel as first-line treatment for metastatic triple-negative breast cancer: Results from the randomised, global phase III CAPItello-290 trial.
P S Schmid, H L McArthur, J Cortés, B Xu, F Cardoso, B Zurawski

Ann Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world treatment patterns of hormone receptor-positive and human epidermal growth factor receptor 2-negative advanced breast cancer.
Barbara Radecka, Bogdan Żurawski, Aleksandra Łacko, Aleksandra Anna Grela-Wojewoda, Karolina Wieruszewska-Kowalczyk

Contemp Oncol (Pozn)· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Simultaneous Durvalumab and Platinum-Based Chemoradiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer: The Phase III PACIFIC-2 Study.
Jeffrey D Bradley, Shunichi Sugawara, Ki Hyeong Lee, Gyula Ostoros, Ahmet Demirkazik, Bogdan Zurawski

J Clin Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial.
N Harbeck, S Modi, L Pusztai, S Ohno, J Wu

Ann Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis